Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.57 |
| ▸ | DAO | P14920 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 9/20 | 0.50 |
| ▸ | SRC | P12931 | 8/20 | 0.50 |
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | DRD3 | P35462 | 2/20 | 0.49 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.49 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.49 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.49 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31088687 | 1.00 | HRH4 (0.57) | HRH4HRH3DAOALOX15HTT | |
| Hydrochloric Acid SCHEMBL1879831 | 0.98 | HRH4 (0.56) | HRH4HRH3DAOALOX15HTT | |
| SCHEMBL832252 | 0.85 | KDM4E (0.58) | HRH4HRH3DAOALOX15HTT | |
| SCHEMBL296469 | 0.81 | HRH4 (0.57) | HRH4HRH3DAOCNR2DRD2 | |
| SCHEMBL9986964 | 0.81 | HRH4 (0.51) | HRH4HRH3DAOCNR2DRD2 | |
| SCHEMBL30229383 | 0.81 | HRH4 (0.51) | HRH4HRH3DAOCNR2DRD2 | |
| SCHEMBL15848423 | 0.81 | RIPK1 (0.62) | HRH4HRH3DAOALOX15CNR2 | |
| SCHEMBL30549017 | 0.80 | DAO (0.59) | HRH4HRH3DAOALOX15HTT | |
| SCHEMBL24740425 | 0.80 | RIPK1 (0.64) | HRH4HRH3DAOALOX15CNR2 | |
| SCHEMBL1647417 | 0.80 | RIPK1 (0.60) | HRH4HRH3DAOCNR2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110312938-A1 | Pyrrolopyridine Carboxylic Acid Derivatives | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | US | claimed |
| WO-2025110815-A1 | IMIDAZO [1,2-B] PYRIDAZINE-BASED NOVEL COMPOUND AS CDK INHIBITOR AND USE THEREOF | 아이리드비엠에스 주식회사 | 2025-05-30 | — | — | WO | disclosed |
| US-20250099462-A1 | Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor | HUTCHISON MEDIPHARMA LTD (CN) | 2025-03-27 | — | — | US | disclosed |
| CN-119325468-A | Heterocyclic derivatives, compositions and uses thereof | 北京丹擎医药科技有限公司 | 2025-01-17 | — | — | CN | disclosed |
| US-20240270757-A1 | SPIROCYCLIC COMPOUNDS | ASTRAZENECA AB (SE) | 2024-08-15 | — | — | US | disclosed |
| EP-4405343-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2024-07-31 | — | — | EP | disclosed |
| EP-3863638-B1 | PHOSPHODIESTERASE INHIBITORS | UNIV NEBRASKA (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20240139182-A1 | Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor | HUTCHISON MEDIPHARMA LTD (CN) | 2024-05-02 | — | — | US | disclosed |
| CN-117916241-A | Spiro compounds | 阿斯利康(瑞典)有限公司 | 2024-04-19 | — | — | CN | disclosed |
| US-11939344-B2 | Spirocyclic compounds | ASTRAZENECA AB (SE) | 2024-03-26 | — | — | US | disclosed |
| WO-2004101563-A1 | AZAINDOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-11-25 | — | — | WO | disclosed |
| EP-1479680-A1 | Azaindole derivatives as Factor Xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2004-11-24 | — | — | EP | disclosed |
| CN-1535272-A | Nitrogen-containing bicyclic heterocycles | ʷ | 2004-10-06 | — | — | CN | disclosed |
| US-20040171620-A1 | Nitrogen-containing bicyclic heterocycles for use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-09-02 | — | — | US | disclosed |
| EP-1399443-A1 | NITROGEN-CONTAINING BICYCLIC HETEROCYCLES FOR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2004-03-24 | — | — | EP | disclosed |
| US-20040038998-A1 | Aminopiperidine quinolines and their azaisosteric analogues with antibacterical activity | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-02-26 | — | — | US | disclosed |
| CN-1452619-A | Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity | SMITHKLINE BEECHAM PLC (GB) | 2003-10-29 | — | — | CN | disclosed |
| WO-2003087098-A1 | NITROGEN-CONTAINING BICYCLIC HETEROCYCLES FOR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-10-23 | — | — | WO | disclosed |
| EP-1305308-A1 | AMINOPIPERIDINE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2003-05-02 | — | — | EP | disclosed |
| WO-2002008224-A1 | AMINOPIPERIDINE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171620-A1 | Nitrogen-containing bicyclic heterocycles for use as antibacterials | NRDC, NUCB2, NDC1 | HRH4 90/4885HRH3 190/4885DAO 411/4885 |
| US-20240270757-A1 | SPIROCYCLIC COMPOUNDS | PKD1, PKD2, CCNI | HRH4 4700/4885HRH3 4808/4885DAO 4592/4885 |
| US-11939344-B2 | Spirocyclic compounds | PKD1, PKD2, NR5A1 | HRH4 4779/4885HRH3 4851/4885DAO 4641/4885 |
| US-20110312938-A1 | Pyrrolopyridine Carboxylic Acid Derivatives | SDHA, ALDH5A1, SDHB | HRH4 582/4885HRH3 696/4885DAO 984/4885 |
| US-20040038998-A1 | Aminopiperidine quinolines and their azaisosteric analogues with antibacterical activity | AZI2, AMPD2, AMPD1 | HRH4 522/4885HRH3 350/4885DAO 93/4885 |
| US-20250099462-A1 | Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor | KCNJ11, NISCH, CYP4Z1 | HRH4 1438/4885HRH3 2410/4885DAO 1917/4885 |
| US-20240139182-A1 | Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor | KCNJ11, NISCH, CYP4Z1 | HRH4 1438/4885HRH3 2410/4885DAO 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.